{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T18:54:16Z","timestamp":1648925656453},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.therap.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,11,19]],"date-time":"2017-11-19T23:32:30Z","timestamp":1511134350000},"page":"291-293","source":"Crossref","is-referenced-by-count":2,"title":["Colite ulc\u00e9r\u00e9e s\u00e9v\u00e8re lors d\u2019un traitement par ipilimumab sans r\u00e9cidive apr\u00e8s cure d\u2019infliximab et relai secondaire par pembrolizumab"],"prefix":"10.1016","volume":"73","author":[{"given":"M\u00e9lissa","family":"Yelehe-Okouma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Granel-Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Hudziak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Schmutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.therap.2017.10.004_bib0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.therap.2017.10.004_bib0115","first-page":"307","article-title":"Modelling comparative efficacy of drugs with different survival profiles: ipilimumab, vemurafenib and dacarbazine in advanced melanoma","volume":"30","author":"Lee","year":"2016","journal-title":"Bio Drugs"},{"issue":"6","key":"10.1016\/j.therap.2017.10.004_bib0120","first-page":"571","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors","volume":"30","author":"Day","year":"2016","journal-title":"Bio Drugs"},{"issue":"6","key":"10.1016\/j.therap.2017.10.004_bib0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1684\/bdc.2013.1771","article-title":"Immune-checkpoints: the new anti-cancer immunotherapies","volume":"100","author":"Ileana","year":"2013","journal-title":"Bull Cancer"},{"issue":"5","key":"10.1016\/j.therap.2017.10.004_bib0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jgo.2016.05.007","article-title":"The development of immunotherapy in older adults: new treatments, new toxicities?","volume":"7","author":"Helissey","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.therap.2017.10.004_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.therap.2017.10.004_bib0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.therap.2017.10.004_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11894-017-0540-6","article-title":"Gastrointestinal and hepatic complications of immune checkpoint inhibitors","volume":"19","author":"Cramer","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"issue":"3","key":"10.1016\/j.therap.2017.10.004_bib0150","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/den.12820","article-title":"Endoscopic findings of ipilimumab-induced colitis","volume":"29","author":"Satoh","year":"2017","journal-title":"Dig Endosc Dig Endosc"},{"issue":"3","key":"10.1016\/j.therap.2017.10.004_bib0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","article-title":"Ipilimumab-induced acute severe colitis treated by infliximab","volume":"23","author":"Pages","year":"2013","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.therap.2017.10.004_bib0160","first-page":"662","article-title":"Management of side effects of immune checkpoint blockade by anti-CTLA-4\u00a0and anti-PD-1\u00a0antibodies in metastatic melanoma","volume":"14","author":"K\u00e4hler","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"10.1016\/j.therap.2017.10.004_bib0165","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1007\/s10620-008-0641-z","article-title":"Cytotoxic T-lymphocyte-associated antigen 4\u00a0antibody-induced colitis and its management with infliximab","volume":"54","author":"Johnston","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.therap.2017.10.004_bib0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/cbr.2008.0607","article-title":"Infliximab in the treatment of anti-CTLA4\u00a0antibody (ipilimumab) induced immune-related colitis","volume":"24","author":"Minor","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.therap.2017.10.004_bib0175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.therap.2017.10.004_bib0180","first-page":"2016","article-title":"Vedolizumab: a novel treatment for ipilimumab-induced colitis","volume":"18","author":"Hsieh","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.therap.2017.10.004_bib0185","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4\u00a0and PD-1\/PD-L1\u00a0inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.therap.2017.10.004_bib0190","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/CJI.0000000000000118","article-title":"Successful anti-PD-1\u00a0antibody treatment in a metastatic melanoma patient with known severe autoimmune disease","volume":"39","author":"Maul","year":"2016","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.therap.2017.10.004_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.therap.2017.10.004_bib0200","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume":"14","author":"Verschuren","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.therap.2017.10.004_bib0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0000000000000165","article-title":"Ipilimumab-induced colitis in patients with metastatic melanoma","volume":"25","author":"De Felice","year":"2015","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.therap.2017.10.004_bib0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salame","year":"2016","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571730183X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571730183X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T05:55:51Z","timestamp":1570341351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571730183X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S004059571730183X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2017.10.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}